A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

NCT06836609 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolic Dysfunction-Associated Steatohepatitis

Interventions

DRUG: ALN-CIDEB
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals